Targeting cerebrovascular Wnt/beta-catenin signaling to reverse brain endothelial damage induced by SARS-CoV-2 infection
- Institution
- UNIVERSITY OF ILLINOIS AT CHICAGO, IL
- Principal investigator
- Sarah Elizabeth Lutz
- Funding
- $801K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
Abstract Many COVID-19 survivors experience long-lasting neurological post-acute sequelae of COVID-19 (NeuroPASC) including cognitive, cerebrovascular, and neurological disorders. The causes of NeuroPASC are not understood. However, evidence suggests that blood-brain barrier damage may contribute to NeuroPASC. Identifying mechanisms that regulate the brain endothelial cell response in NeuroPASC is therefore important. Wnt/β-catenin signaling plays a critical role in maintaining integrity of the blood-brain barrier. This grant will test the novel mechanism that Wnt/β-catenin dysregulation in brain endothelial cells contributes to NeuroPASC by increasing blood-brain barrier permeability and neuroinflammation. We will determine the effect of age on brain endothelial cell signaling and blood-brain barrier permeability for the resolution of NeuroPASC. We will define the mechanism by which Wnt/β-catenin activation reverses blood-brain barrier leakage and memory impairment in NeuroPASC. We will determine the extent through which transcellular blood-brain barrier permeability contributes to NeuroPASC. These studies could identify future therapeutic strategies leveraging Wnt/β-catenin signaling to improve chronic post-infectious neurological diseases.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF ILLINOIS AT CHICAGO
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of Illinois at ChicagoNot yet scored
Impact of SARS-CoV-2 on the cerebrovasculature as a risk factor for VCID: Role of Wnt/beta-catenin
Sarah Elizabeth Lutz · $2.5M · 2025–2029
- NIH · University of Illinois at Chicago47
MASLD protection by STAT5-regulated transcription factors
Rhonda D Kineman · $825K · 2025–2030
- NIH · University of Illinois at Chicago47
Identifying a novel pathway that regulates RA immunometabolism
Shiva Shahrara · $715K · 2022–2028